Gastroesophageal Cancer
Advertisement
Matthew Strickland, MD, discusses the current management of defective mismatch repair in gastroesophageal adenocarcinoma.
The effects of primary tumor and LN volume on clinical outcomes in ESCC following neoadjuvant CCRT and surgery are unknown.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
The prognostic value of the Edmonton Symptom Assessment Scale in patients with gastroesophageal cancer was investigated.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Chromoendoscopic screening can help reduce esophageal cancer incidence and mortality rates.
The trial’s primary endpoint was safety and the secondary endpoint was feasibility.
Tislelizumab correlated with a higher objective response rate and a better durable antitumor response versus chemotherapy.
Research has shown that trifluridine-tipiracil may increase survival benefit for patients with metastatic EGA.
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Patients received 2 cycles of sintilimab, paclitaxel, and carboplatin once every 21 days.
Results of the PANDA study show that atezo has an additive effect with chemo in eliciting tumor response in early G/GEJ.
The study investigated if avelumab and paclitaxel plus ramucirumab would constitute an effective second-line treatment.
The ESCORT-NEO study explored the use of neoadjuvant camrelizumab with chemotherapy followed by adjuvant camrelizumab.
Twice-weekly docetaxel plus 5-FU has previously exhibited encouraging antitumor activity.
Manish A. Shah, MD, and colleagues are reporting 5-year follow-up data from the randomized, phase 3 KEYNOTE-590 study.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.